Cancer Drug Shortages Persist Across U.S.
THURSDAY, Oct. 5, 2023 (HealthDay News) — U.S. cancer centers continue to have shortages of commonly used chemotherapy drugs, a new survey shows, though the medications are not as scarce as they were last June.The National Comprehensive Cancer Networ…
Learn MoreMujeres otorgan mejor calificación a la reconstrucción mamaria con tejido autólogo
MIÉRCOLES, 4 de octubre de 2023 (HealthDay News) – Las mujeres que se someten a una reconstrucción mamaria utilizando su propio tejido en lugar de implantes podrían estar más satisfechas con los resultados, indica una nueva investigación.”Los hallazgo…
Learn MoreGemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published online Oct. 2 in Nature Medicine.
Matthew D. Galsky, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a phase 2 study of 76 patients with MIBC who received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients who achieved a clinical complete response (cCR) could proceed without cystectomy.
Of the patients, 33 achieved a cCR (43 percent); 32 of the 33 opted to forgo immediate cystectomy. The researchers found that the positive predictive value of cCR for a composite outcome of two-year metastasis-free survival in patients forgoing immediate cystectomy or ATM, RB1, FANCC, and ERCC2) or increased tumor mutational burden. There was an association noted between the baseline and on-treatment immune contexture with clinical outcomes.
“Treatment for muscle-invasive bladder cancer is in need of major improvements from both a quality-of-life and an effectiveness standpoint,” Galsky said in a statement. “If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer.”
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Learn MoreShorter Course of Radiation May Be Safe for Women Undergoing Breast Reconstruction
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — Breast cancer patients who undergo a mastectomy can probably benefit from a shorter course of more intense radiation therapy, a new study indicates.Hypofractionated radiation therapy — which provides a highe…
Learn MoreMachine Learning Can Better ID Who Needs Lung Cancer Screening
TUESDAY, Oct. 3, 2023 (HealthDay News) — A machine learning model that uses only data on age, smoking duration, and pack-years can predict lung cancer risk and identify who needs lung cancer screening with better performance than currently used metho…
Learn MoreDiversity in Early-Phase Cancer Trials Improved Since 2000
TUESDAY, Oct. 3, 2023 (HealthDay News) — There have been some increases in diversity in early-phase cancer clinical trials since 2000, according to a study presented at the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Et…
Learn MoreWomen Give High Marks to Breast Reconstruction Using Patient’s Own Tissue
TUESDAY, Oct. 3, 2023 (HealthDay News) – Women who have breast reconstruction using their own tissue instead of implants ma be more satisfied with the results, new research shows.”The findings were unexpected, since autologous breast reconstruction is…
Learn MoreMost Adolescent Vapers Do Not Use Cessation Resources
MONDAY, Oct. 2, 2023 (HealthDay News) — Most adolescent electronic cigarette users do not use cessation resources in their attempts to quit, according to a study published online Oct. 2 in Pediatrics.Hongying Daisy Dai, Ph.D., from the University of …
Learn MoreLa FDA comenzará a regular miles de pruebas de laboratorio
LUNES, 2 de octubre de 2023 (HealthDay News) – Frente a crecientes informes de pruebas clínicas de laboratorio inexactas, la Administración de Alimentos y Medicamentos de EE. UU. (FDA, por sus siglas en inglés) anunció el viernes que por primera vez r…
Learn MoreThreshold of 6 mm on Retropharyngeal Lymph Node Predicts PFS in Nasopharyngeal Carcinoma
MONDAY, Oct. 2, 2023 (HealthDay News) — For patients with nasopharyngeal carcinoma (NPC), a minimal axial diameter (MAD) threshold of 6 mm for retropharyngeal lymph node (RLN) predicts survival, according to a study published online Sept. 27 in the A…
Learn More